---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-024648"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:27:01.168068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ionis Q1 revenue $119M, loss $150M; WAINUA launch delivers $1M royalty; olezarsen NDA filed for FCS

## Summary
- Q1 total revenue $119M, down 9% YoY from $131M; GAAP operating loss $150M vs $114M prior year.
- SPINRAZA royalties $38M (down from $50M); WAINUA contributed $1M royalty in first partial quarter of launch.
- Cash and short-term investments $2.2B; 2024 financial guidance reaffirmed.
- Olezarsen NDA submitted to FDA for FCS; positive Phase 3 donidalorsen data for HAE, preparing regulatory submissions.
- Pipeline progress: eplontersen fast track for ATTR cardiomyopathy, bepirovirsen fast track for CHB, ION224 positive Phase 2 for MASH.

## SEC filing metadata
- accession: 0001140361-24-024648
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/0001140361-24-024648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/ef20028585_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-024648
- JSON: https://secwatch.observer/filing/0001140361-24-024648.json
- Plain text: https://secwatch.observer/filing/0001140361-24-024648.txt

## Key facts
- Earnings Releases
  IONIS PHARMACEUTICALS INC updated its first quarter ended March 31, 2024 guidance (reaffirmed).
  - Period: first quarter ended March 31, 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 7, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/0001140361-24-024648-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.